K. Boér

发表

Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC) — A Hungarian experience in the BCIRG 001 trial

T. Pintér, J. Szántó, K. Boér, 2009, Pathology Oncology Research.

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.

P. Fasching, F. Couch, K. Gelmon, 2021, European journal of cancer.

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

I. Láng, A. Llombart-Cussac, N. Sanders, 2012, Investigational New Drugs.

Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer

K. Boér, 2016, OncoTargets and therapy.

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

R. Finn, T. Pintér, J. Crown, 2012 .

Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer

Z. Horváth, M. Dank, B. Pikó, 2022, Pathology & Oncology Research.

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

M. Piccart, J. Baselga, A. Ballestrero, 2019, The Lancet. Oncology.

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

R. Finn, Marcus Schmidt, I. Bondarenko, 2014 .

Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience

Z. Horváth, T. Csoszi, B. Budai, 2021, Pathology & Oncology Research.

AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy

Tae-You Kim, I. Láng, J. Douillard, 2008 .

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

R. Finn, Marcus Schmidt, I. Bondarenko, 2017 .

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

OTT_A_309862 3971..3981

M. Dank, Z. Abonyi-Tóth, K. Boér, 2021 .

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

K. Wilner, R. Finn, Marcus Schmidt, 2020, Breast Cancer Research and Treatment.

A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.

E. Hitre, I. Láng, Z. Horváth, 2013, Journal of clinical and diagnostic research : JCDR.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Xin Huang, Johannes Ettl, Marcus Schmidt, 2015, The Lancet. Oncology.

Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine.

A. Falus, Z. Pós, K. Dede, 2008, European journal of cell biology.

Impact of systemic histamine deficiency on the crosstalk between mammary adenocarcinoma and T cells.

S. Tóth, A. Falus, V. Molnár, 2007, Journal of pharmacological sciences.

New drug development

O. S. Zhukova, Guy Jerusalem, Robert Millham, 2012 .

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

R. Finn, Marcus Schmidt, I. Bondarenko, 2016, Breast Cancer Research.

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Tae-You Kim, I. Láng, J. Douillard, 2011, Investigational New Drugs.

Fulvestrant in advanced breast cancer: evidence to date and place in therapy

K. Boér, 2017, Therapeutic advances in medical oncology.

[Systemic treatment of breast cancer: professional guideline].

Z. Horváth, M. Dank, B. Pikó, 2020, Magyar onkologia.

[Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].

T. Pintér, I. Láng, J. Szántó, 2003, Magyar onkologia.

LBA10_PRPrimary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)

M. Piccart, J. Baselga, A. Ballestrero, 2017 .

[Adjuvant chemotherapy of early stage breast cancer].

K. Boér, 2010, Orvosi hetilap.

Advantages of 18F FDG-PET/CT over Conventional Staging for Sarcoma Patients

K. Borbély, Z. Nemeth, K. Boér, 2017, Pathology & Oncology Research.

Expression of histidine decarboxylase in human colonic cancer cells and adenomatous polyps

A. Falus, K. Boér, I. Kaszás, 2003, Inflammation Research.

[Clinical use of 18F-FDG PET/CT in colorectal carcinoma].

K. Borbély, Z. Nemeth, M. Kásler, 2013, Orvosi hetilap.

P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.

D. Amadori, R. Finn, T. Pintér, 2011 .

Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2− Advanced Breast Cancer: A Nationwide Real-World Experience

M. Dank, Z. Abonyi-Tóth, K. Boér, 2021, OncoTargets and therapy.

[Pharmaceutical therapy of breast cancer].

T. Pintér, I. Láng, Z. Horváth, 2010, Magyar Onkológia.

impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer

K. Boér, 2016 .